Active substances
Olodaterol + Tiotropium
- SFDA 2
- US FDA 1
- Health Canada 1
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SPIOLTO RESPIMAT | 2.5,2.5 µg,µg | inhalation solution · Inhalation use | 1 Cartridge | SAR 178.70 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
| SPIOLTO RESPIMATE | 2.5,2.5 µg,µg | inhalation solution · Inhalation use | 1 Cartridge | SAR 200.05 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
Indications — CHI Daman Drug Formulary
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| STIOLTO RESPIMAT | EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH | spray, metered · inhalation | BOEHRINGER INGELHEIM | Prescription | 21 May 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| INSPIOLTO RESPIMAT | 02441888 | 2.5 MCG / ACT; 2.5 MCG / ACT | SOLUTION · INHALATION | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Tiotropium bromide 2.5micrograms/dose / Olodaterol 2.5micrograms/dose inhalation solution cartridge CFC free | £32.50 | 60 dose | 1 Oct 2026 |
| NHS Drug Tariff | Tiotropium bromide 2.5micrograms/dose / Olodaterol 2.5micrograms/dose solution for inhalation cartridge with device CFC free | £32.50 | 60 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.